Modest success of multikinase inhibitors (MKIs) paved the way for more selective RET inhibitors, which have now become first-line therapies for RET-altered cancers ((Kurzrock et al. 2011), Wells et al. 2012, Wirth et al. 2020). The gene discussed is RET; the disease is cancer.